Oral Micronized Progesterone in Adolescents (Ages 12 to 17): Off-Label Use, Dosing, and Safety

What Is Oral Micronized Progesterone and Why Is It Used Off-Label in Adolescents?

Oral micronized progesterone (OMP), sold under the brand name Prometrium, is a bioidentical hormone derived from plant sterols and formulated in peanut oil to improve absorption. The FDA approved it in 1998 for secondary amenorrhea and endometrial protection in postmenopausal women receiving conjugated estrogen. No pediatric indication exists. Physicians who prescribe it to adolescents ages 12 to 17 are acting outside that label, relying on adult pharmacokinetic data, small adolescent studies, and professional society guidance to justify use.

Why the Off-Label Gap Exists

Pharmaceutical companies rarely fund pediatric clinical trials for hormonal agents because the regulatory pathway is complex and the commercial market is smaller. The result is that OMP's safety and efficacy data in patients under 18 come largely from case series, retrospective reviews, and extrapolation from adult trials rather than from randomized controlled trials in adolescents. The FDA's Best Pharmaceuticals for Children Act (BPCA) has not yet compelled a pediatric study of Prometrium. Prescribers therefore bear a higher burden of clinical justification.

The Bioidentical Distinction

OMP is structurally identical to endogenous progesterone, which matters in adolescents whose hypothalamic-pituitary-gonadal (HPG) axis is still maturing. Synthetic progestins such as medroxyprogesterone acetate bind glucocorticoid and androgen receptors in addition to progesterone receptors, producing effects that differ from native progesterone. A 2019 analysis in the Journal of Clinical Endocrinology and Metabolism confirmed that OMP more closely replicates physiologic luteal-phase progesterone profiles than synthetic alternatives [1]. That distinction drives some clinicians to favor OMP over synthetic progestins for adolescent patients, even without a direct head-to-head pediatric trial.

Which Adolescent Conditions Drive Off-Label Prescribing?

Off-label OMP prescribing in the 12 to 17 age group clusters around three clinical scenarios: menstrual irregularity stemming from functional hypothalamic amenorrhea, primary amenorrhea workup management, and luteal phase support in adolescents with polycystic ovary syndrome (PCOS) who have had a withdrawal bleed established on combined hormonal therapy.

Functional Hypothalamic Amenorrhea (FHA)

FHA is the most common non-anatomic cause of secondary amenorrhea in adolescent girls, accounting for roughly 35% of cases in the 15 to 19 age group [2]. Energy deficiency (often associated with the female athlete triad or relative energy deficiency in sport, RED-S) suppresses GnRH pulsatility, reducing LH and FSH secretion, which in turn drops estradiol and progesterone to prepubertal levels. The Endocrine Society's 2017 Clinical Practice Guideline on FHA states: "We suggest against prescribing combined oral contraceptives (COCs) as first-line treatment for FHA-associated amenorrhea because COCs may mask recovery." The same guideline acknowledges that cyclic progestin can be used to induce withdrawal bleeding while nutritional and behavioral causes are addressed [3].

OMP at 200 mg orally for 10 days will induce a withdrawal bleed in most patients with adequate endogenous estrogen priming. A positive withdrawal bleed confirms sufficient estradiol, reassuring clinicians that bone mineral density (BMD) accrual is not critically impaired. If no bleed occurs, the patient likely has hypoestrogenemia severe enough to require estrogen replacement in addition to progesterone.

Primary Amenorrhea Evaluation

Primary amenorrhea, defined as no menarche by age 15 in a patient with normal secondary sexual development or by age 13 in a patient with no breast development, triggers a structured workup involving pelvic ultrasound, karyotype, and hormone panels [4]. A progesterone challenge (100 to 200 mg OMP for 10 days) is sometimes used diagnostically: a withdrawal bleed indicates an intact outflow tract and adequate estrogen. This use is diagnostic rather than therapeutic and requires only a short course of OMP. The American College of Obstetricians and Gynecologists (ACOG) supports progesterone challenge testing in the context of amenorrhea workup, though it cautions that a failed challenge does not definitively exclude anatomic outflow obstruction [4].

PCOS-Related Luteal Phase Insufficiency

Adolescents with PCOS frequently have anovulatory cycles, meaning progesterone secretion in the second half of the menstrual cycle is absent or blunted. Unopposed estrogen stimulation of the endometrium raises the theoretical risk of endometrial hyperplasia over time, though clinically significant hyperplasia in teenagers is rare. Cyclic OMP (100 to 200 mg for 12 to 14 days per month) provides endometrial protection while avoiding the androgenic side effects of some synthetic progestins. A 2021 systematic review in Reproductive BioMedicine Online found that OMP produced fewer metabolic adverse effects than medroxyprogesterone acetate when used for endometrial protection in anovulatory patients, though the review included very few subjects under 18 [5].

Pharmacokinetics in Adolescents vs. Adults

Adult pharmacokinetic data show that a single 200 mg oral dose of OMP produces a peak serum progesterone concentration (Cmax) of roughly 17 ng/mL at 2 to 3 hours post-dose, with a half-life of 16 to 18 hours [6]. Bioavailability is approximately 10% due to extensive first-pass hepatic metabolism to inactive glucuronide conjugates.

Does Adolescent Physiology Alter These Parameters?

No dedicated pharmacokinetic study of OMP in patients aged 12 to 17 has been published as of this article's review date. Clinicians extrapolate from adult data with the assumption that hepatic CYP3A4 activity, the primary enzyme responsible for progesterone metabolism, reaches near-adult levels by mid-puberty (Tanner stage 3 to 4). Body weight and fat distribution differences may affect volume of distribution. Adolescents with low body weight (common in FHA) may achieve higher serum concentrations per milligram of dose, which argues for starting at 100 mg rather than 200 mg.

Food Effects and Timing

Taking OMP with food increases absorption approximately 3-fold compared to a fasted state [6]. The FDA-approved prescribing information for Prometrium specifies that it should be taken with food. Bedtime dosing is standard because sedation is the most common adverse effect and is less new when the patient is already sleeping.

Dosing Protocols Used in Clinical Practice

No pediatric dosing guidelines exist in the Prometrium prescribing information. The following protocols represent off-label clinical practice informed by adult data and published expert opinion.

Progesterone Challenge (Diagnostic Use)

• OMP 200 mg orally at bedtime for 10 consecutive days.
• Assess for withdrawal bleed within 2 to 7 days of completing the course.
• A bleed of any volume constitutes a positive response.

Cyclic Endometrial Protection in Anovulatory Adolescents

• OMP 100 to 200 mg orally at bedtime for 12 to 14 days per calendar month, or days 15 to 28 of a 28-day cycle.
• Repeat monthly while anovulation persists.
• Liver function tests and clinical assessment every 6 months.

FHA with Adequate Estrogen (Withdrawal Bleed Induction)

• OMP 200 mg orally at bedtime for 10 days, typically initiated after confirming serum estradiol above 40 pg/mL.
• Repeat every 1 to 3 months to prevent endometrial buildup while the primary energy and nutritional deficit is addressed.

The framework above represents clinical synthesis by the HealthRX medical team from adult prescribing information, Endocrine Society FHA guidelines, and ACOG amenorrhea practice bulletins. No published pediatric-specific dosing table currently exists for OMP in the 12 to 17 age group.

Safety Profile and Adverse Effects in the Adolescent Context

The adverse effect profile of OMP in adolescents is extrapolated primarily from adult trial data, since pediatric-specific safety studies are lacking. The most relevant concerns are CNS depression, allergic reactions, and effects on the developing HPG axis.

CNS and Sedation Effects

OMP is metabolized in part to allopregnanolone, a neurosteroid that acts as a positive allosteric modulator of GABA-A receptors. This produces dose-dependent sedation, dizziness, and impaired coordination. In the key adult trials supporting Prometrium's approval, somnolence occurred in up to 27% of participants at 200 mg doses [6]. Adolescents should be warned not to drive or operate machinery for at least 4 hours after a dose.

Allergic and Hypersensitivity Reactions

Prometrium capsules are formulated in peanut oil. Any adolescent with a known peanut allergy should not receive Prometrium. Prescribers must document allergy screening before the first prescription. An alternative compounded aqueous suspension of micronized progesterone, free of peanut oil, may be prepared by a compounding pharmacy, though this route carries its own regulatory and quality considerations.

Effects on the HPG Axis

Exogenous progesterone suppresses GnRH pulsatility through negative feedback at the hypothalamus and pituitary. In adults, cyclic low-dose OMP has not been shown to suppress ovulation during the follicular phase because it is administered only during the luteal phase of the cycle. However, if OMP is given continuously or at high doses, gonadotropin suppression sufficient to inhibit ovulation is possible [7]. In adolescents with a still-maturing HPG axis, this effect may be clinically meaningful, and prescribers should avoid continuous high-dose regimens unless specifically indicated.

Bone Mineral Density Considerations

Progesterone deficiency during adolescence may impair peak bone mass accrual. Estrogen is the dominant driver of BMD in this age group, but progesterone has direct anabolic effects on osteoblasts via progesterone receptors expressed in bone tissue [8]. Correcting progesterone deficiency with OMP may confer some BMD benefit, though this has not been demonstrated in a controlled adolescent trial. The greater contributor to BMD impairment in FHA is hypoestrogenemia, which requires separate treatment if present.

Prescribing Considerations and Informed Consent

Off-label prescribing is legal and common in pediatric medicine, but it carries heightened documentation requirements. Prescribers should obtain written informed consent from the adolescent patient and the parent or legal guardian, explaining:

1. The drug's lack of FDA approval for patients under 18.
2. The rationale for choosing OMP over alternatives (synthetic progestins, no treatment).
3. Known adverse effects from adult data and their expected applicability.
4. The monitoring plan, including periodic labs, symptom review, and re-evaluation of the underlying diagnosis.

The American Academy of Pediatrics (AAP) policy statement on off-label drug use states that "the use of a drug for an unlicensed indication does not necessarily imply that it is experimental or that its use is inappropriate," but it underscores the clinician's responsibility to document the evidence basis for every such prescription [9].

Drug Interactions Relevant to Adolescents

CYP3A4 inducers common in adolescents (carbamazepine, rifampin, topiramate used for migraines or seizures) may accelerate progesterone metabolism and reduce serum levels. CYP3A4 inhibitors (fluconazole, some macrolide antibiotics, grapefruit juice in large quantities) may increase progesterone exposure and amplify sedative effects. A medication reconciliation review before prescribing OMP is standard practice [6].

Monitoring Protocol

• Baseline: serum LH, FSH, estradiol, progesterone (day 21 of cycle if cycling), TSH, prolactin, pelvic ultrasound.
• At 3 months: symptom review, withdrawal bleed history, liver function tests if other hepatotoxic drugs are co-prescribed.
• At 6 months and annually: repeat pelvic ultrasound if anovulatory, reassess indication and continued need.

Comparing OMP to Synthetic Progestins in Adolescents

Clinicians choosing a progestogen for an adolescent patient typically weigh OMP against medroxyprogesterone acetate (MPA, Provera) or norethindrone. Each has trade-offs.

| Agent | Receptor Selectivity | Sedation Risk | Metabolic Effects | Pediatric RCT Data | |---|---|---|---|---| | OMP (Prometrium) | Progesterone-selective | High (allopregnanolone) | Neutral to favorable | None | | MPA (Provera) | Progesterone + glucocorticoid + androgen | Low | Adverse lipid profile | Limited | | Norethindrone | Progesterone + androgen | Low | Mild androgenic | Very limited |

MPA has been prescribed to adolescents for decades and clinicians have broader practical experience with it. OMP's bioidentical structure and neutral metabolic profile make it attractive for longer-term cyclic use, but the sedation burden may limit adherence in school-age patients.

A 2020 retrospective chart review published in the Journal of Pediatric and Adolescent Gynecology (N=87 adolescents with FHA, mean age 16.2 years) found that patients who received cyclic OMP for induced withdrawal bleeding reported higher satisfaction scores and fewer mood-related side effects than those who received MPA, though both groups had similar rates of menstrual cycle restoration at 12 months [10].

Regulatory Status and the Path to Pediatric Data

The FDA has not issued a written request (WR) under BPCA or a required pediatric study (RPCA) for progesterone in patients under 18. The drug's patent expired decades ago, eliminating the commercial incentive for a manufacturer-sponsored pediatric trial. Academic investigators have proposed pediatric pharmacokinetic studies through the NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), but no results appear in ClinicalTrials.gov registrations as of July 2025.

The Endocrine Society's 2017 FHA guideline and ACOG's Practice Bulletin 150 on amenorrhea both acknowledge off-label progestogen use in adolescents as acceptable practice in specific circumstances, stopping short of recommending OMP by name over synthetic alternatives [3,4]. Both documents call for more pediatric-specific data.

Key Contraindications Applicable to Adolescents

• Known or suspected pregnancy.
• Undiagnosed abnormal vaginal bleeding.
• Known peanut allergy (Prometrium formulation).
• Active thromboembolic disorder or history of hormone-related thromboembolism.
• Known or suspected hormone-sensitive malignancy.
• Severe hepatic impairment.
• Concurrent use of strong CYP3A4 inhibitors without dose adjustment.

Adolescents with Turner syndrome or other chromosomal causes of ovarian failure require estrogen replacement as the primary therapy; adding OMP without adequate estrogen priming serves no endometrial protective function and does not induce a withdrawal bleed.